Company intelligence / Profile preview

GILUPI

Potsdam, Brandenburg, Germany

Ownership: Private
Employees: ~25
Development stage: Other

Overview

GILUPI is a German biotech company specializing in in vivo isolation of circulating tumor cells (CTCs) via its proprietary CellCollector® platform, supporting liquid biopsy for real-time, minimally invasive cancer diagnostics and therapy monitoring. The technology enables enumeration and molecular characterization of CTCs, aiding in personalized oncology care. Its main application is in prostate cancer, with ongoing expansion into other cancers like non-small cell lung cancer and pancreatic cancer[1][2][6].

Therapeutic areas: Oncology
Modalities: Device
Industry: Molecular Diagnostics

Partnerships

VIROAD (strategic partner and major investor)

Beyond the preview

Go deeper on GILUPI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GILUPI.

Explore the full profile